Get the Stockscreener App
2.565
3.57%
-0.095
After Hours:
2.57
0.005
+0.19%
Orchestra Biomed Holdings Inc stock is traded at $2.565, with a volume of 237.11K.
It is down -3.57% in the last 24 hours and down -12.16% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$2.66
Open:
$2.67
24h Volume:
237.11K
Relative Volume:
0.78
Market Cap:
$99.12M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-1.71
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
-5.35%
1M Performance:
-12.16%
6M Performance:
-54.76%
1Y Performance:
-57.67%
1-Day Range:
$2.56
$2.68
1-Week Range:
$2.50
$2.75
52-Week Range:
$2.37
$7.04
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.565 | 143.51M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Does Orchestra BioMed Holdings Inc. fit your quant trading modelJobs Report & AI Forecast Swing Trade Picks - Newser
Understanding Orchestra BioMed Holdings Inc.’s price movementJuly 2025 Price Swings & AI Based Buy and Sell Signals - Newser
Best data tools to analyze Orchestra BioMed Holdings Inc. stockJuly 2025 Recap & Free Technical Pattern Based Buy Signals - Newser
Will Orchestra BioMed Holdings Inc. continue its uptrendWeekly Trend Recap & Free Weekly Watchlist of Top Performers - Newser
Will Orchestra BioMed Holdings Inc. see short term momentum2025 Technical Overview & Reliable Volume Spike Alerts - Newser
Real time scanner hits for Orchestra BioMed Holdings Inc. explainedTrade Risk Assessment & Daily Volume Surge Trade Alerts - Newser
Why Orchestra BioMed Holdings Inc. stock attracts strong analyst attentionMarket Activity Recap & Risk Controlled Stock Pick Alerts - Newser
Orchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA Milestones - MyChesCo
Is Orchestra BioMed Holdings Inc. stock bottoming outWeekly Trade Analysis & Proven Capital Preservation Tips - Newser
Is a relief rally coming for Orchestra BioMed Holdings Inc. holdersWeekly Volume Report & Short-Term High Return Strategies - Newser
Should you wait for a breakout in Orchestra BioMed Holdings Inc.2025 Macro Impact & Daily Entry Point Trade Alerts - Newser
FDA Greenlights Broader Patient Access for AVIM Therapy Trial in Pacemaker Patients - MSN
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction - The Manila Times
Orchestra BioMed Announces Publication of AVIM Therapy - GlobeNewswire
Novel Heart Therapy Shows Dual Benefits: Reduces Blood Pressure While Improving Cardiac Function - Stock Titan
Signal strength of Orchestra BioMed Holdings Inc. stock in tech scannersWeekly Investment Report & Community Trade Idea Sharing - Newser
Detecting support and resistance levels for Orchestra BioMed Holdings Inc.Weekly Trend Report & Accurate Intraday Trading Signals - Newser
Reversal indicators forming on Orchestra BioMed Holdings Inc. stock2025 Top Gainers & Scalable Portfolio Growth Methods - Newser
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates - MSN
Advanced analytics toolkit walkthrough for Orchestra BioMed Holdings Inc.July 2025 Momentum & Stepwise Entry/Exit Trade Alerts - Newser
Why Orchestra BioMed Holdings Inc. is moving todayRate Cut & AI Enhanced Trading Signals - Newser
How to integrate Orchestra BioMed Holdings Inc. into portfolio analysis toolsMarket Trend Review & High Conviction Buy Zone Alerts - Newser
What the charts say about Orchestra BioMed Holdings Inc. today [Quarterly Portfolio Report]Daily Chart Pattern Signals - Newser
What data driven models say about Orchestra BioMed Holdings Inc.’s future [Day Trade] - Newser
Can Orchestra BioMed Holdings Inc. hit a new high this monthJuly 2025 Price Swings & Fast Entry Momentum Trade Alerts - Newser
Can you recover from losses in Orchestra BioMed Holdings Inc.Free Weekly Chart Analysis With Entry Advice - Newser
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - GlobeNewswire
Orchestra BioMed: A High-Risk, High-Reward Play in Cardiovascular Innovation - AInvest
Orchestra BioMed raises $111mln, achieves multiple FDA milestones. - AInvest
Orchestra BioMed Lands $111M Strategic Investment and FDA Breakthrough Status for Heart Disease Tech - Stock Titan
Orchestra BioMed Holdings, Inc. SEC 10-Q Report - TradingView
What data driven models say about Orchestra BioMed Holdings Inc.’s futureFree AI Powered High Return Stock Calls - Newser
Does Orchestra BioMed Holdings Inc. show high probability of reboundStock Price Prediction Using AI Tools - Newser
LGND: Getting In Tune with MedTech - Yahoo Finance
Applying sector rotation models to Orchestra BioMed Holdings Inc.Conservative Asset Allocation Risk Analysis - Newser
Intrinsic Value of Orchestra BioMed Holdings Inc. Stock: Is It Undervalued or OvervaluedCapital Safe Picks with Consistent Gains - Newser
Orchestra BioMed Holdings Inc. stock trend outlook and recovery pathFree Pattern Detection for Entry Confirmation - Newser
Long term hold vs stop loss in Orchestra BioMed Holdings Inc.Consistent Return Setup with Exit Strategy - Newser
Is Orchestra BioMed Holdings Inc. a candidate for recovery playAnnual Market Behavior and Sector Summary - Newser
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):